Smith & Nephew plc (NYSE:SNN) Shares Sold by Tpg Gp A LLC

Tpg Gp A LLC lessened its holdings in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 69.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 456,206 shares of the medical equipment provider's stock after selling 1,028,575 shares during the quarter. Tpg Gp A LLC owned 0.10% of Smith & Nephew worth $11,214,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sei Investments Co. increased its position in Smith & Nephew by 229.8% during the 4th quarter. Sei Investments Co. now owns 75,215 shares of the medical equipment provider's stock worth $1,849,000 after purchasing an additional 52,411 shares in the last quarter. Townsquare Capital LLC increased its position in Smith & Nephew by 19.0% during the 4th quarter. Townsquare Capital LLC now owns 17,557 shares of the medical equipment provider's stock worth $432,000 after purchasing an additional 2,798 shares in the last quarter. Barclays PLC purchased a new position in Smith & Nephew in the 4th quarter worth approximately $431,000. Blue Trust Inc. boosted its holdings in Smith & Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock worth $144,000 after acquiring an additional 1,213 shares during the period. Finally, ABC Arbitrage SA purchased a new position in Smith & Nephew in the 4th quarter worth approximately $4,847,000. Institutional investors and hedge funds own 25.64% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on SNN shares. StockNews.com upgraded Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. HSBC cut Smith & Nephew from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Hsbc Global Res cut Smith & Nephew from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. UBS Group cut Smith & Nephew from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group upped their price target on Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a report on Thursday, May 1st. Six investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $28.00.

Smith & Nephew Stock Performance

Smith & Nephew stock opened at $28.83 on Monday. The stock has a market cap of $12.63 billion, a P/E ratio of 13.35, a price-to-earnings-growth ratio of 1.26 and a beta of 0.68. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average of $27.42 and a 200-day moving average of $26.27. Smith & Nephew plc has a 52 week low of $23.69 and a 52 week high of $31.72.

Smith & Nephew Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.447 per share. This is a boost from Smith & Nephew's previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. The ex-dividend date is Friday, March 28th. Smith & Nephew's dividend payout ratio is 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.